Corbus Pharmaceuticals Holdings, Inc. CRBP
3.38 USD -0.02 (-0.44%)
Regular-session close
3.38 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
3.00 Day range 3.62
2.81 52-week range 12.88
- YTD
- -58.54%
- 1 year
- -69.51%
News
benzinga.com Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
globenewswire.com Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026 CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed Corresponding significant reductions were also seen…benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $23 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $24 to $23.
benzinga.com RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33 RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.
benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.
benzinga.com Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.20) by 50.83 percent. This is a 4.74 percent increase over…
globenewswire.com Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of…benzinga.com Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase…
